Frankfurt - Delayed Quote EUR

Verona Pharma plc (I9SA.F)

49.00

-0.20

(-0.41%)

At close: April 17 at 3:29:02 PM GMT+2

Ritedose to double single-vial packaging capabilities with seventh Syntegon line

The new packaging system will increase Ritedose's annual processing range by between 160 and 170 million vials.

Packaging Gateway 2 days ago

VRNA
Verona Pharma to Report First Quarter 2025 Financial Results and Provide Corporate Update

LONDON and RALEIGH, N.C., April 15, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that it will report its financial results for the first quarter ended March 31, 2025 on Tuesday, April 29, 2025 and host an investment community conference call at 9:00 a.m. EDT / 2:00 p.m. BST to discuss these financial results and provide a corporate update. To participate, please dial one of the following numbers and ask to join the Verona Pharma call: +1-

GlobeNewswire 4 days ago

VRNA
Verona Pharma Announces Amended Strategic Financing with Oaktree and OMERS

RIPSA interests repurchased Term loan facility increased to $450 million with more favorable terms Access to up to an additional $200 million LONDON and RALEIGH, N.C., March 28, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a biopharmaceutical company focused on respiratory diseases, has amended its existing strategic financing agreements by repaying the revenue interest purchase and sale agreement (“RIPSA”) and increasing the debt facility to $450

GlobeNewswire 22 days ago

VRNA
Jim Cramer Advises Caution on Verona Pharma (VRNA): “Risky – Sell Half and Let the Rest Ride”

We recently published a list of Jim Cramer Focused On These 9 Stocks Recently. In this article, we are going to take a look at where Verona Pharma plc (NASDAQ:VRNA) stands against other stocks that Jim Cramer discussed recently. Jim Cramer, host of Mad Money, expressed his frustration on March 19 about how investors often […]

Insider Monkey 24 days ago

VRNA
Is Verona Pharma plc (VRNA) the Best Performing Growth Stock in 2025?

We recently published a list of 10 Best Performing Growth Stocks in 2025 In this article, we are going to take a look at where Verona Pharma plc (NASDAQ:VRNA) stands against other best performing growth stocks in 2025. Heavy AI investments and the tariffs uncertainty have been putting pressure on the technology and growth sector. […]

Insider Monkey last month

VRNA
Verona Pharma plc (VRNA): A Bull Case Theory

We came across a bullish thesis on Verona Pharma plc (VRNA) on Value Investing Subreddit Page by loud_keyb. In this article, we will summarize the bulls’ thesis on VRNA. Verona Pharma plc (VRNA)’s share was trading at $67.50 as of March 4th. VRNA’s forward P/E was 434.78 according to Yahoo Finance. Verona Pharma (VRNA) has reported strong […]

Insider Monkey last month

VRNA
Beat the Market the Zacks Way: Verona, Visa, Starbucks in Focus

Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our key performance data from the past three months.

Zacks last month

^GSPC

VRNA

USAC
Earnings Beat: Verona Pharma plc (NASDAQ:VRNA) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

Investors in Verona Pharma plc ( NASDAQ:VRNA ) had a good week, as its shares rose 2.5% to close at US$69.63 following...

Simply Wall St. last month

VRNA
Verona Pharma PLC (VRNA) Q4 2024 Earnings Call Highlights: Strong Launch of Ohtuvayre Amid ...

Despite a successful product launch and robust market penetration, Verona Pharma PLC (VRNA) faces increased expenses and a net loss, with a focus on achieving cash flow break-even.

GuruFocus.com last month

VRNA
Verona Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

OhtuvayreTM (ensifentrine) recorded net product sales of $36.6 million in Q4 and $42.3 million in 2024 More prescriptions filled through February 2025 than in Q4 2024 Over 4,600 unique prescribers with ~55% of Tier 1 HCPs prescribing Ohtuvayre through February 2025 Phase 2 programs in bronchiectasis and fixed-dose combination in COPD advance Conference call today at 9:00 a.m. EST / 2:00 p.m. GMT LONDON and RALEIGH, N.C., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona

GlobeNewswire last month

VRNA
Verona Pharma plc (VRNA): The Best Performing Pharma Stock So Far in 2025?

We recently published a list of the 10 Best Performing Pharma Stocks So Far in 2025. In this article, we are going to take a look at where Verona Pharma plc (NASDAQ:VRNA) stands against the other best performing pharma stocks so far in 2025. What’s Going on in the Pharma Sector? On February 20, Jared […]

Insider Monkey last month

VRNA
Verona Pharma Announces March 2025 Investor Conference Participation

LONDON and RALEIGH, N.C., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that senior management will present a company overview at the following conferences in March 2025: TD Cowen 45th Annual Health Care ConferenceDate: Monday, March 3, 2025Time: 11:10 a.m. ET / 4:10 p.m. GMTLocation: Boston, MA Leerink Partners 2025 Global Healthcare ConferenceDate: Monday, March 10, 2025Time: 8:40 a.m. ET / 1:40 p.m. GMTLocation: Miami, FL A web

GlobeNewswire last month

VRNA
Verona Pharma to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Corporate Update

LONDON and RALEIGH, N.C., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that it will report its financial results for the fourth quarter and full year ended December 31, 2024 on Thursday, February 27, 2025 and host an investment community conference call at 9:00 a.m. EST / 2:00 p.m. GMT to discuss these financial results and provide a corporate update. To participate, please dial one of the following numbers and ask to join the Ve

GlobeNewswire 2 months ago

VRNA
What Makes Verona Pharma (VRNA) a Good Fit for 'Trend Investing'

If you are looking for stocks that are well positioned to maintain their recent uptrend, Verona Pharma (VRNA) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

Zacks 2 months ago

VRNA
Here's Why 'Trend' Investors Would Love Betting on Verona Pharma (VRNA)

Verona Pharma (VRNA) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.

Zacks 2 months ago

VRNA
Is Verona Pharma (VRNA) Among Billionaire Joseph Edelman’s Long-Term Stock Picks?

We recently published a list of Billionaire Joseph Edelman’s Top 10 Long-Term Stock Picks. In this article, we are going to take a look at where Verona Pharma plc (NASDAQ:VRNA) stands against other Billionaire Joseph Edelman’s long-term stock picks. Joseph Edelman is a renowned figure in the investment world, recognized for his expertise in biotechnology […]

Insider Monkey 2 months ago

VRNA
Why Verona Pharma, A Triple-Digit Gainer In 2024, Surged Another 19% This Week

Verona Pharma stock hit a record high Thursday on continued enthusiasm for its newly launched COPD treatment, Ohtuvayre.

Investor's Business Daily 3 months ago

VRNA
Wall Street Analysts See a 30.65% Upside in Verona Pharma (VRNA): Can the Stock Really Move This High?

The average of price targets set by Wall Street analysts indicates a potential upside of 30.7% in Verona Pharma (VRNA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Zacks 3 months ago

VRNA
Verona Pharma (VRNA) Upgraded to Buy: What Does It Mean for the Stock?

Verona Pharma (VRNA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks 3 months ago

VRNA
Analysts Expect Breakeven For Verona Pharma plc (NASDAQ:VRNA) Before Long

Verona Pharma plc ( NASDAQ:VRNA ) is possibly approaching a major achievement in its business, so we would like to...

Simply Wall St. 3 months ago

VRNA

Performance Overview

Return	I9SA.F	MSCI WORLD (^990100-USD-STRD)
YTD	+7.93%	-6.25%
1-Year	+226.67%	+6.77%
3-Year	+1,210.16%	+16.08%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Verona Pharma plc (I9SA.F)

Ritedose to double single-vial packaging capabilities with seventh Syntegon line

Verona Pharma to Report First Quarter 2025 Financial Results and Provide Corporate Update

Verona Pharma Announces Amended Strategic Financing with Oaktree and OMERS

Jim Cramer Advises Caution on Verona Pharma (VRNA): “Risky – Sell Half and Let the Rest Ride”

Is Verona Pharma plc (VRNA) the Best Performing Growth Stock in 2025?

Verona Pharma plc (VRNA): A Bull Case Theory

Beat the Market the Zacks Way: Verona, Visa, Starbucks in Focus

Earnings Beat: Verona Pharma plc (NASDAQ:VRNA) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

Verona Pharma PLC (VRNA) Q4 2024 Earnings Call Highlights: Strong Launch of Ohtuvayre Amid ...

Verona Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Verona Pharma plc (VRNA): The Best Performing Pharma Stock So Far in 2025?

Verona Pharma Announces March 2025 Investor Conference Participation

Verona Pharma to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Corporate Update

What Makes Verona Pharma (VRNA) a Good Fit for 'Trend Investing'

Here's Why 'Trend' Investors Would Love Betting on Verona Pharma (VRNA)

Is Verona Pharma (VRNA) Among Billionaire Joseph Edelman’s Long-Term Stock Picks?

Why Verona Pharma, A Triple-Digit Gainer In 2024, Surged Another 19% This Week

Wall Street Analysts See a 30.65% Upside in Verona Pharma (VRNA): Can the Stock Really Move This High?

Verona Pharma (VRNA) Upgraded to Buy: What Does It Mean for the Stock?

Analysts Expect Breakeven For Verona Pharma plc (NASDAQ:VRNA) Before Long

Performance Overview